



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**April 15, 2014 6:00 – 8:15 p.m.  
\*\*\* Please note new times \*\*\***

- 1. Executive Session** **6:00 - 6:15**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes** **6:15 - 6:20**  
(Public Comment Prior to Board Action)
  
- 3. DVHA Pharmacy Administration Updates** **6:20 - 6:25**
  - Updates
  
- 4. Medical Director Update** **6:25 - 6:30**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meetings** **6:30 – 7:00**
  - Dexilant<sup>®</sup> (dexlansoprazole)
  - Hepatitis C Medications
  - Xyrem<sup>®</sup> (Sodium Oxybate)
  
- 6. RetroDUR/DUR** **7:00 – 7:15**
  - Mental Health Medications in Children, SFY 2009, 2011 and 2013
  
- 7. Clinical Update: Drug Reviews** **7:15 – 7:40**  
(Public comment prior to Board action)

**Abbreviated New Drug Reviews**

- Aciphex<sup>®</sup> Sprinkles (rabeprazole) DR Capsules
- Bethikis<sup>®</sup> (tobramycin) Ampule for Inhalation
- Glycate<sup>®</sup> (glycopyrrolate) Oral Tablet

**Full New Drug Reviews**

- Adempas<sup>®</sup> (riociguat) Oral Tablet
- Brintellix<sup>®</sup> (vortioxetine) Oral Tablet
- Fetzima<sup>®</sup> (levomilnacipran) ER Oral Capsule

- 8. Therapeutic Drug Classes – Periodic Review** **7:40 – 8:00**  
(Public comment prior to Board action)
- Analgesics: Topical NSAID
  - Anticoagulants: Oral (see stroke prevention below)
  - Antihypertensives: Beta Blockers
  - Antihypertensives: Calcium Channel Blockers
  - Dermatological: Antifungals
  - Immunomodulators (new indications)
  - Platelet Aggregation Inhibitors
  - Smoking Cessation Products
- 9. Clinical Update: New/Updated Clinical Guidelines** **8:00– 8:05**  
(Public comment prior to Board action)
- American Academy of Neurology (AAN) Guidelines on Stroke Prevention in Nonvalvular Atrial Fibrillation (NVAf)
- 10. New Managed Therapeutic Drug Classes** **8:05– 8:05**  
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:05 – 8:10**  
(Public comment prior to Board action)
- Gastrointestinal: Proton Pump Inhibitors (compound suspension kits)
  - Smoking Cessation Products (see therapeutic class review above)
- 12. General Announcements** **8:10– 8:15**  
**Selected FDA Safety Alerts**
- FDA Drug Safety Communication: FDA clarifies Warning about Pediatric Use of Revatio<sup>®</sup> (sildenafil) for Pulmonary Arterial Hypertension
- 13. Adjourn** **8:15**